George Clinical has announced Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA.
George Clinical, headquartered in Sydney, Australia, operates in 15 countries around the world and has major operational hubs in the USA, East Asia, China, and India. Reabold, who is USA-based, will be leading our Business Development team in North America and Europe. Reabold came to George Clinical with 20 years on the sponsor side of the business and understands the challenges facing biopharma companies when executing and outsourcing their clinical trials. The last 10 years have been spent developing solutions in partnership with pharma and biotech clients, working for some large and smaller CROs. He brings a broad spectrum of knowledge to the team including expertise in oncology, renal, diabetes, cardiovascular and CNS.
"This is truly a great opportunity to work with and lead an organization with a strong people-first culture that focuses on improving the medical care of patients while contributing to scientific advancement in chronic diseases and oncology,” Matthew said. “Our model is unique within the CRO industry in that we lead with science and a singular focus on translating that science into operational value for our clients."
"We are excited that Matthew, with his focus on customer service and his abilities to assemble a strong team, will lead Business Development in the USA to accomplish our goals as a global organization," said Mr. Sean Hart, Managing Director, USA and Global Head of Late Phase Studies.